ArticleFolia microbiologica2025
Vector-borne diseases and their role in COVID-19 dynamics and death rates: focus on India.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As one of the most significant global health emergencies, COVID-19 has placed extraordinary demands on healthcare systems worldwide. In India, its widespread transmission has been influenced by the country's diverse climatic conditions, geo-ecological complexity, and dense population. This, vector-borne diseases (VBDs)-including malaria, dengue, kala azar, Japanese encephalitis, and chikungunya-have long posed additional challenges to public health infrastructure. Intriguingly, prior exposure to these diseases may shape immune responses, potentially conferring cross-protection against multiple pathogens. A cross-sectional study aimed at assessing the role of VBDs in COVID-19 incidence and mortality revealed a multifaceted relationship. Prior dengue exposure was linked to an increased risk of SARS-CoV-2 infection and mortality, whereas kala azar, Japanese encephalitis, and chikungunya appeared to have protective influences. Notably, malaria had statistically significant protective effects against both SARS-CoV-2 infection and mortality (p < 0.04). These findings suggest that immune mechanisms-such as cross-reactive antibodies or immune regulation-may alter susceptibility to COVID-19. Given the substantial protective effect of malaria, further investigation is warranted to clarify the underlying biological processes involved. Insights from this study could guide public health strategies, optimize resource allocation, and refine intervention measures in regions where both COVID-19 and VBDs remain major concerns.
Indexed as
Identifiers
40783477What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.